Table 1.
Epidemiological characteristics of the 4 included articles that presented longitudinal data
| Author | Autoimmune disease | Medications | Cases (n) |
Population (n) |
Screening time (years) | Period detection rate/100,000 | Detection rate/100,000/year |
|---|---|---|---|---|---|---|---|
| Lopes 2015 [35] | Juvenile Lupus Erythematosus | Prednisone, Hydroxychloroquine, Mycophenolate mofetil, Cyclophosphamide | 1 | 312 | 32 | 320.50 | 10.02 |
| Burmester 2016 [36] | Rheumatoid Arthritis | Tocilizumab | 1 | 1262 | 2 | 79.20 | 39.62 |
| Titton 2011 [23] | Rheumatic Diseases; | Anti-TNF and DMARDs | 1 | 1037 | 0.83 | 96.43 | 116.18 |
| Wallis RS 2005 [31] | Not clear | Infliximab | 1 | 197,000 | 4 | 0.51 | 0.13 |
| Total* | – | – | 4 | 199,611 | – | 2.00 | – |
n Number of patients, DMARDs Disease-modifying antirheumatic drugs, * Unadjusted values